Clinical trials: B Chronic Lymphocytic Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is either proactively reduced or reactively modified in response to…
- Trial name
- TAILOR (NCT05963074)
- Testing
- Ibrutinib, Venetoclax
- Where
- 74 sites in United States, Canada and 6 more
- Volunteers
- 333 people
- Sponsor
- Janssen Research & Development, LLC
Leukemia
Immunotherapy With CD19 CAR T-cells for B-Cell Leukemia
This study aims to evaluate the safety, efficacy and duration of response of CD19 Chimeric Antigen Receptor (CAR) redirected autologous T-cells in patients with high risk, relapsed CD19+ haematological malignancies.
- Trial name
- NCT04100187
- Testing
- Anti-CD19-CAR
- Volunteers
- 100 people
- Sponsor
- Kecellitics Biotech Company Ltd
B-Cell Chronic Lymphocytic Leukemia
Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients
The purpose of this research study is to find out what effects (good and bad) the combination of Nipent+Cytoxan+Rituxan has on CLL cancer compared to Fludara+Cytoxan+Rituxan.
- Trial name
- NCT00254163
- Testing
- Fludarabine, Cyclophosphamide, Rituximab
- Where
- 11 sites in United States
- Volunteers
- 184 people
- Sponsor
- US Oncology Research
Relapsed or Refractory Chronic Lymphocytic Leukemia
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL
A Phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
- Trial name
- NCT03739554
- Testing
- CYC065, Venetoclax
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
Cutaneous T-cell Lymphoma (CTCL), Mycosis Fungoides (MF)
Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL
Objectives of this clinical trial are to evaluate the safety, tolerability, pharmacokinetics and potential efficacy of the investigational drug, cobomarsen (MRG-106), in patients diagnosed with certain lymphomas and leukemias…
- Conditions
- Cutaneous T-cell Lymphoma (CTCL), Mycosis Fungoides (MF), Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-Cell Lymphoma (DLBCL), ABC Subtype
- Trial name
- NCT02580552
- Testing
- Cobomarsen
- Where
- 19 sites in United States
- Volunteers
- 66 people
- Sponsor
- miRagen Therapeutics, Inc.
B-cell Lymphoma, Chronic Lymphocytic Leukemia
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
The study will evaluate NX-5948 (bexobrutideg) in combination with venetoclax with or without an anti-CD20 antibody (rituximab or obinutuzumab) in second-line or higher (2L+) relapsed/refractory (R/R) or first-line (1L) chronic…
- Conditions
- B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- NCT07520006
- Testing
- NX-5948, venetoclax, rituximab
- Where
- 9 sites in United States
- Volunteers
- 150 people
- Sponsor
- Nurix Therapeutics, Inc.
B-cell Chronic Lymphocytic Leukemia
A Phase I/II Study to Assess the Safety and Tolerability of APO866 for the Treatment of Refractory B-CLL
This phase I/II study is designed to determine the safety and tolerability of APO866 for the treatment of refractory B-CLL not amenable to aHSCT.
- Trial name
- NCT00435084
- Testing
- APO866
- Where
- 4 sites in United Kingdom
- Volunteers
- 10 people
- Sponsor
- Valerio Therapeutics
Leukemia, Lymphocytic, Chronic, B-Cell
Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
The trial is a Phase II, open label, Simon's two stage study design to evaluate the efficacy and safety of Tenalisib in patients with CLL who have relapsed or are refractory after at least one prior therapy.
- Trial name
- NCT04204057
- Testing
- Tenalisib
- Where
- 6 sites in Bulgaria, Georgia and 1 more
- Volunteers
- 21 people
- Sponsor
- Rhizen Pharmaceuticals SA
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries, representing approximately 30% of all adult leukemias.
- Trial name
- NCT05105841
- Testing
- Venetoclax, Ibrutinib, Obinutuzumab
- Where
- 20 sites in Japan
- Volunteers
- 20 people
- Sponsor
- AbbVie
Non Hodgkin Lymphoma, Richter Transformation
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing…
- Conditions
- Non Hodgkin Lymphoma, Richter Transformation, Multiple Myeloma, T-cell-prolymphocytic Leukemia
- Trial name
- NCT04771572
- Testing
- LP-118
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- Newave Pharmaceutical Inc
Chronic Lymphocytic Leukemia (CLL)
Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia
The objective of the first part of the study is to determine a safe dose of TRU-016 that can be used in combination with bendamustine in patients with relapsed CLL.
- Trial name
- NCT01188681
- Testing
- TRU-016 and bendamustine, Bendamustine, 15 mg/kg TRU-016 and bendamustine
- Where
- 25 sites in United States, Austria and 3 more
- Volunteers
- 79 people
- Sponsor
- Aptevo Therapeutics
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies
Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory hematologic malignancies, however not all tumors respond or remain in response to CD19 targeted CAR-T cells.
- Conditions
- Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Hairy Cell Leukemia, Multiple Myeloma
- Trial name
- NCT07679919
- Testing
- LMY-922
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Luminary Therapeutics
Chronic Lymphocytic Leukemia
Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia
The purposes of this study are to determine a maximum tolerated dose and to evaluate the safety and efficacy of CP-461 in patients with Chronic Lymphocytic Leukemia.
- Trial name
- NCT00036257
- Testing
- CP-461
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- Astellas Pharma Inc
Leukemia, Myelodysplastic Syndromes
Chemotherapy in Treating Patients Who Have Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of DX-8951f in treating patients who have hematologic…
- Trial name
- NCT00004047
- Testing
- exatecan mesylate
- Where
- United States
- Sponsor
- Daiichi Sankyo
Lymphoma, Including Chronic Lymphocytic Leukemia, Solid Tumors
A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax
This is an open-label, single or multiple center study to determine the interaction of rifampin with navitoclax (ABT-263) in approximately 12 subjects with cancer.
- Trial name
- NCT01121133
- Testing
- navitoclax, Rifampin
- Volunteers
- 12 people
- Sponsor
- AbbVie
Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer.
- Conditions
- Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
- Trial name
- BRUIN-CLL-314 (NCT05254743)
- Testing
- Pirtobrutinib, Ibrutinib
- Where
- 143 sites in United States, Argentina and 21 more
- Volunteers
- 737 people
- Sponsor
- Loxo Oncology, Inc.
Follicular Lymphoma, Small Lymphocytic Lymphoma
Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma
This is a phase 2, open label study to assess umbralisib in combination with ublituximab in participants with treatment naïve Follicular Lymphoma (FL) and Small Lymphocytic Lymphoma (SLL).
- Trial name
- NCT03828448
- Testing
- Ublituximab, Umbralisib
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- TG Therapeutics, Inc.
Leukemia
Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Oblimersen may help fludarabine and cyclophosphamide kill more cancer cells by making them more sensitive to…
- Trial name
- NCT00024440
- Testing
- filgrastim, oblimersen sodium, cyclophosphamide
- Where
- United States
- Sponsor
- Genta Incorporated
Chronic Lymphocytic Leukemia (CLL)
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)
This study is being conducted to demonstrate the superiority in progression-free survival (PFS) of dinaciclib compared to ofatumumab in chronic lymphocytic leukemia (CLL) participants with del 17p or in the overall population who…
- Trial name
- NCT01580228
- Testing
- Dinaciclib, Ofatumumab
- Volunteers
- 44 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Lymphocytic Leukemia
A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period
The main purpose of the study is to evaluate if adding venetoclax to participants receiving cBTKi for the 1L CLL can achieve deep durable remissions of undetectable measurable residual disease [uMRD < or 10^-4 in peripheral blood…
- Trial name
- BRAVE (NCT06524375)
- Testing
- Venetoclax, cBTKi Monotherapy
- Where
- 20 sites in United States
- Volunteers
- 118 people
- Sponsor
- Genentech, Inc.